Ocugen Provides Business Update & Third Quarter 2022 Financial Results
08 nov. 2022 07h30 HE
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trialExpanded product pipeline with OCU500—Ocugen’s...
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
27 oct. 2022 07h30 HE
|
Ocugen
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
19 oct. 2022 07h30 HE
|
Ocugen
Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the...
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
12 oct. 2022 17h37 HE
|
Ocugen
• No safety concerns noted in ongoing clinical trial• Study timeline remains on track MALVERN, Pa., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a...
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
06 oct. 2022 08h00 HE
|
Ocugen
MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
29 sept. 2022 07h30 HE
|
Ocugen
MALVERN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
28 sept. 2022 06h30 HE
|
Ocugen
Ocugen’s intranasal candidate is one of the world’s most advanced intranasal COVID-19 vaccinesIntranasal vaccine is designed to curb virus transmission and confer protective immunity MALVERN, Pa.,...
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 sept. 2022 17h07 HE
|
Ocugen
MALVERN, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology
14 sept. 2022 06h30 HE
|
Ocugen
Data include the persistence of immune responses and protection against variants of concern, especially Delta and Omicron Ocugen has North American commercialization rights for BBV152, commercialized...
Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
08 sept. 2022 07h30 HE
|
Ocugen
MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...